BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: García AM, Salado IG, Perez DI, Brea J, Morales-García JA, González-García A, Cadavid MI, Loza MI, Luque FJ, Perez-Castillo A, Martinez A, Gil C. Pharmacological tools based on imidazole scaffold proved the utility of PDE10A inhibitors for Parkinson's disease. Future Med Chem 2017;9:731-48. [PMID: 28485668 DOI: 10.4155/fmc-2017-0005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Huang J, Tang D, Cao Y, Wang Y, Long J, Wei L, Song H. Inhibition of PDE10A-Rescued TBI-Induced Neuroinflammation and Apoptosis through the cAMP/PKA/NLRP3 Pathway. Evid Based Complement Alternat Med 2022;2022:3311250. [PMID: 35463083 DOI: 10.1155/2022/3311250] [Reference Citation Analysis]
2 Luo L, Zhang Y, Hsu C, Korshunov VA, Long X, Knight PA, Berk BC, Yan C. Role of PDE10A in vascular smooth muscle cell hyperplasia and pathological vascular remodeling. Cardiovasc Res 2021:cvab304. [PMID: 34550322 DOI: 10.1093/cvr/cvab304] [Reference Citation Analysis]
3 Eliewi AG, Al-garawi ZS, Al-kazzaz FF, Atia AJK. Multi target-directed imidazole derivatives for neurodegenerative diseases. J Phys : Conf Ser 2021;1853:012066. [DOI: 10.1088/1742-6596/1853/1/012066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Wang Y, Gao H, Jiang S, Luo Q, Han X, Xiong Y, Xu Z, Qiao R, Yang X. Principal component analysis of routine blood test results with Parkinson's disease: A case-control study. Exp Gerontol 2021;144:111188. [PMID: 33279667 DOI: 10.1016/j.exger.2020.111188] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 de Araújo JS, García-Rubia A, Sebastián-Pérez V, Kalejaiye TD, Bernardino da Silva P, Fonseca-Berzal CR, Maes L, De Koning HP, Soeiro MNC, Gil C. Imidazole Derivatives as Promising Agents for the Treatment of Chagas Disease. Antimicrob Agents Chemother 2019;63:e02156-18. [PMID: 30670432 DOI: 10.1128/AAC.02156-18] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
6 Botros SS, William S, Sabra AA, El-Lakkany NM, Seif El-Din SH, García-Rubia A, Sebastián-Pérez V, Blaazer AR, de Heuvel E, Sijm M, Zheng Y, Salado IG, Munday JC, Maes L, de Esch IJP, Sterk GJ, Augustyns K, Leurs R, Gil C, De Koning HP. Screening of a PDE-focused library identifies imidazoles with in vitro and in vivo antischistosomal activity. Int J Parasitol Drugs Drug Resist 2019;9:35-43. [PMID: 30669086 DOI: 10.1016/j.ijpddr.2019.01.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
7 Sebastián-Pérez V, Hendrickx S, Munday JC, Kalejaiye T, Martínez A, Campillo NE, de Koning H, Caljon G, Maes L, Gil C. Cyclic Nucleotide-Specific Phosphodiesterases as Potential Drug Targets for Anti-Leishmania Therapy. Antimicrob Agents Chemother 2018;62:e00603-18. [PMID: 30104270 DOI: 10.1128/AAC.00603-18] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
8 García AM, Brea J, González-García A, Pérez C, Cadavid MI, Loza MI, Martinez A, Gil C. Targeting PDE10A GAF Domain with Small Molecules: A Way for Allosteric Modulation with Anti-Inflammatory Effects. Molecules 2017;22:E1472. [PMID: 28869560 DOI: 10.3390/molecules22091472] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
9 Bolognesi ML. Neurodegenerative drug discovery: building on the past, looking to the future. Future Medicinal Chemistry 2017;9:707-9. [DOI: 10.4155/fmc-2017-0087] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]